SubsidieMeestersImaging Single Glycoconjugates
GlycoX develops single molecule imaging methods to elucidate glycoconjugate structures, enhancing understanding for therapeutics and diagnostics in immune response and microbial infection.
Projectdetails
Introduction
GlycoX aims to develop single molecule analytical methods to address the challenge of elucidating glycoconjugate structures. Glycoconjugates are glycans (a.k.a carbohydrates) that are attached to other biomolecules such as proteins or lipids. Glycoconjugates are essential to all living organisms, carrying out key cell-cell communication roles in the immune system or in microbial infection.
Importance of Glycoconjugates
Glycoconjugates are found in all biological systems and yet, when compared to proteins or nucleotides, very little is known about their structures and how they lead to their biochemical properties or how they can be exploited in therapeutics. Efforts to reveal their structures by ensemble averaged approaches, whether primary structures (sequences) or secondary structures (conformations), have been severely hampered by the high complexity and flexibility of glycans.
Methodology
GlycoX addresses this challenge by direct imaging of single glycoconjugate molecules, devoid of any ensemble averaging. To this end, glycoconjugate ions generated from electrospray ionization are soft landed on a surface and imaged one-at-a-time by scanning probe microscopy in vacuo.
Project Goals
The Project proposes the use of direct imaging to:
- Identify the glycoforms of any glycoconjugates (i.e., variants of a specific glycoconjugate that possess different glycan primary structures).
- Sequence any glycan residues in any glycoconjugates.
- Determine the conformations of any glycoconjugates.
Focus Areas
The Project plans to focus on glycoconjugates that are intractable by present analytical methods, many of which are central in:
- The immune system
- Microbial infection
- Emerging diagnostics, drugs, and vaccines
Impact
These works have far-reaching impacts:
- Shedding light into the language used by cells to communicate and by pathogens to infect.
- Creating new opportunities in glycan-based therapeutics.
- Opening new frontiers in single molecule analytical chemistry of biomolecules.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.000.000 |
| Totale projectbegroting | € 2.000.000 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 30-4-2028 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolutionGlyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment. | ERC Starting... | € 1.500.000 | 2023 | Details |
GlycoRoads: A platform for the de novo design of glycansGlycoRoads aims to develop an AI-driven platform for de novo glycan design using molecular dynamics simulations to create a comprehensive database, enhancing customization for therapeutic and material applications. | ERC Proof of... | € 150.000 | 2025 | Details |
Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infectionGLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment. | ERC Consolid... | € 1.994.024 | 2024 | Details |
Imaging Ultrafast Single Particle Macromolecular Dynamics with X-ray LasersThis project aims to develop ultrafast single-protein imaging using XFEL technology to enhance understanding of macromolecular dynamics and structural changes in biological processes. | ERC Consolid... | € 2.000.000 | 2024 | Details |
In situ structural biology of human immune defenceDeveloping super-resolution cryo-correlative light and electron microscopy (SRcryoCLEM) to enhance in situ structural biology for antibody-mediated immunity and therapeutic advancements. | ERC Consolid... | € 1.976.553 | 2025 | Details |
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution
Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.
GlycoRoads: A platform for the de novo design of glycans
GlycoRoads aims to develop an AI-driven platform for de novo glycan design using molecular dynamics simulations to create a comprehensive database, enhancing customization for therapeutic and material applications.
Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infection
GLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment.
Imaging Ultrafast Single Particle Macromolecular Dynamics with X-ray Lasers
This project aims to develop ultrafast single-protein imaging using XFEL technology to enhance understanding of macromolecular dynamics and structural changes in biological processes.
In situ structural biology of human immune defence
Developing super-resolution cryo-correlative light and electron microscopy (SRcryoCLEM) to enhance in situ structural biology for antibody-mediated immunity and therapeutic advancements.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Inhibitor-Mediated Programming of GlycoformsThe project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions. | EIC Pathfinder | € 2.998.878 | 2025 | Details |
Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseasesThe project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications. | EIC Pathfinder | € 3.920.718 | 2024 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Universal GPCR Activity Sensor for Next Generation Drug DiscoveryThis project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures. | EIC Pathfinder | € 2.965.384 | 2023 | Details |
Computation driven development of novel vivo-like-DNA-nanotransducers for biomolecules structure identificationThis project aims to develop DNA-nanotransducers for real-time detection and analysis of conformational changes in biomolecules, enhancing understanding of molecular dynamics and aiding drug discovery. | EIC Pathfinder | € 3.000.418 | 2022 | Details |
Inhibitor-Mediated Programming of Glycoforms
The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.
Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseases
The project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications.
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.
Universal GPCR Activity Sensor for Next Generation Drug Discovery
This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.
Computation driven development of novel vivo-like-DNA-nanotransducers for biomolecules structure identification
This project aims to develop DNA-nanotransducers for real-time detection and analysis of conformational changes in biomolecules, enhancing understanding of molecular dynamics and aiding drug discovery.